Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.

Next Previous
Trial Profile

Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine; Vindesine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 03 Mar 2011 Additional lead trial centre and investigators identified as reported by ClinicalTrials.gov.
  • 27 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 27 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top